Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incidence and survival of hepatocellular carcinoma in type 2 diabetes with cirrhosis treated with metformin
TCTR20200604001Completed
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of metformin in type 2 diabetes mellitus (T2DM), Cirrhosis and hepatocellular carcinoma (HCC), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Primary endpoints: Incidence of hepatocellular carcinoma and Survival in hepatocellular carcinoma. Started Aug 2019; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)Cirrhosishepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20200604001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200604001.